by B2i | Jul 26, 2023 | Press Releases
JUPITER, Fla., July 26, 2023 — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
by B2i | Jul 24, 2023 | Press Releases
Dosing of patients completed at the end of FebruaryData Safety Monitoring Board conducted analysis of Day 29 data No major vaccine-related safety concerns for either of the two dose levelsNo Serious Adverse Events (SAE’s) or Adverse Events of Special Interest...
by B2i | Jun 21, 2023 | Press Releases
JUPITER, Fla. and DHAKA, Bangladesh, June 21, 2023 — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building...
by B2i | Jun 1, 2023 | Press Releases
JUPITER, Fla., June 01, 2023 — Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein...
by B2i | May 10, 2023 | Press Releases
New research collaboration with a Top 5 pharmaceutical company to develop C1 expressed vaccine antigen for human healthExpanded licensing agreement with Rubic One Health (“Rubic”) to develop, manufacture and commercialize affordable vaccines and biologics...
by B2i | May 10, 2023 | Press Releases
JUPITER, Fla., May 10, 2023 — Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein...
